Fujian Cosunter Pharmaceutical , Ltd. EBIT

As of the most recent data (June 2026), 300436.SZ shows a EBIT of $-190M. That compares with $-140M in the prior-year period — down 30.8% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 300436.SZ's EBIT is now $-190M (was $-140M) — a 30.8% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Fujian Cosunter Pharmaceutical , Ltd. is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Fujian Cosunter Pharmaceutical , Ltd. is at $-190M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how 300436.SZ stacks up against individual peers as well.

Tracking 300436.SZ's ebit over time shows whether Fujian Cosunter Pharmaceutical , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $-190M That compares with $-140M in the prior-year period — down 30.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Fujian Cosunter Pharmaceutical , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-190M) with ownership activity and broader fundamentals.